Role of sequencing in therapy selection.
J Acquir Immune Defic Syndr
; 29 Suppl 1: S19-27, 2002 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-11832698
ABSTRACT
The goals of sequencing antiretroviral agents are to preserve as many treatment options as possible, minimize drug toxicity, and prolong suppression of HIV. There are numerous options for sequencing antiretroviral agents when treatment fails. The most common reasons for treatment failure are the emergence of resistance and poor adherence. Data indicate that protease inhibitor therapy enhanced by ritonavir may delay the development of resistance longer than nonboosted protease inhibitor therapy. The results of using efavirenz or abacavir to simplify protease inhibitor treatment regimens for HIV-suppressed patients are promising. Although resistance to nonnucleoside reverse transcriptase inhibitors is a serious problem, sequencing them after zidovudine or abacavir therapy may be effective because of the hypersusceptibility to nonnucleoside reverse transcriptase inhibitors exhibited by viral populations in many nucleoside reverse transcriptase inhibitor-experienced patients. New antiretrovirals with greater tolerability, higher genetic barriers, and less cross-resistance than existing agents are needed to achieve further dramatic advances in treating HIV infection.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Síndrome de Inmunodeficiencia Adquirida
/
Terapia Antirretroviral Altamente Activa
Límite:
Humans
Idioma:
En
Revista:
J Acquir Immune Defic Syndr
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2002
Tipo del documento:
Article
País de afiliación:
Estados Unidos